Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) at CSIR-Central Food Technological Research Institute, Mysore, India. In his 11 years of research, he has published more than 18 research articles in reputed international journals, along with 4 books and 11 book chapters. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology associated with targeting virulent factors of diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, USA, on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in the Indian Science Congress and the Agriculture, Nutrition and Health Academy, UK. Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals. Dr. Divya Singh is presently working as a scientist in Central Sericultural Research and Training Institute, Mysore, India. Her research specialization is primarily in genetics, proteomics, metabolomics, toxicology, bioinformatics, and molecular biological evaluation in various in vivo and in vitro plant models to elucidate the physiological changes and evaluate the DNA damage potency. She has published morethan 10 research articles including book chapters. In addition, she is also a life member fellow of Indian Science Congress. Dr. Rajesh Kumar Singh is currently working as a Research Associate in Banaras Hindu University. His research focus is pharmacognosy, reverse pharmacology, drug design and discovery, extraction & isolation of natural products, cell culture, and handling of different rodents. He has published several research articles in reputable journals over the course of his career. At present, he is involved in developing an Indian origin cell line and screening drugs of natural origin for the treatment of gallbladder cancer.

• 1. A historical review and future prospective of chemical carcinogenesis2. Role of xenobiotics metabolism in carcinogenesis3. Recalcitrant of toxic xenobiotics and its routes of exposure to human4. Major environmental xenobiotics risk for different cancers5. Toxicokinetic and toxicodynamic of xenobiotics in cancer development 6. Mechanism of oxidative stress in carcinogenesis induced by xenobiotics7. Genotoxic and non-genotoxic activities of cancer-inducing xenobiotics8. Modulation of epigenome by xenobiotics in cancer9. Carcinogenic effects of nanomaterials with emphasis on nanoplastics10. Endocrine disruptor activity of xenobiotics in carcinogenesis11. Environmental exposures (Bisphenol A and phatalates) as xenoestrogens enhance risk for breast cancer12. Biotransformation of toxic xenobiotics by human gut microbiota13. Mechanism of resistance to toxic xenobiotics in human14. Profiling the reactive metabolites of xenobiotics in cancer15. Toxicogenomic for prediction of carcinogenicity of xenobiotic substances

Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) at CSIR-Central Food Technological Research Institute, Mysore, India. In his 11 years of research, he has published more than 18 research articles in reputed international journals, along with 4 books and 11 book chapters. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology associated with targeting virulent factors of diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, USA, on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in the Indian Science Congress and the Agriculture, Nutrition and Health Academy, UK. Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals. Dr. Divya Singh is presently working as a scientist in Central Sericultural Research and Training Institute, Mysore, India. Her research specialization is primarily in genetics, proteomics, metabolomics, toxicology, bioinformatics, and molecular biological evaluation in various in vivo and in vitro plant models to elucidate the physiological changes and evaluate the DNA damage potency. She has published morethan 10 research articles including book chapters. In addition, she is also a life member fellow of Indian Science Congress. Dr. Rajesh Kumar Singh is currently working as a Research Associate in Banaras Hindu University. His research focus is pharmacognosy, reverse pharmacology, drug design and discovery, extraction & isolation of natural products, cell culture, and handling of different rodents. He has published several research articles in reputable journals over the course of his career. At present, he is involved in developing an Indian origin cell line and screening drugs of natural origin for the treatment of gallbladder cancer.

• 1. A historical review and future prospective of chemical carcinogenesis2. Role of xenobiotics metabolism in carcinogenesis3. Recalcitrant of toxic xenobiotics and its routes of exposure to human4. Major environmental xenobiotics risk for different cancers5. Toxicokinetic and toxicodynamic of xenobiotics in cancer development 6. Mechanism of oxidative stress in carcinogenesis induced by xenobiotics7. Genotoxic and non-genotoxic activities of cancer-inducing xenobiotics8. Modulation of epigenome by xenobiotics in cancer9. Carcinogenic effects of nanomaterials with emphasis on nanoplastics10. Endocrine disruptor activity of xenobiotics in carcinogenesis11. Environmental exposures (Bisphenol A and phatalates) as xenoestrogens enhance risk for breast cancer12. Biotransformation of toxic xenobiotics by human gut microbiota13. Mechanism of resistance to toxic xenobiotics in human14. Profiling the reactive metabolites of xenobiotics in cancer15. Toxicogenomic for prediction of carcinogenicity of xenobiotic substances

Dr. Akhileshwar Kumar Srivastava works as a Research Associate (ICMR) at CSIR-Central Food Technological Research Institute, Mysore, India. In his 11 years of research, he has published more than 18 research articles in reputed international journals, along with 4 books and 11 book chapters. His research specialization is primarily in the area of pharmacognosy with genetics, metabolomics, bioinformatics, and molecular biology associated with targeting virulent factors of diseases. In addition, he has studied at Augusta University (formerly, Georgia Regents University) in Augusta, GA, USA, on a J-1 Exchange Scholar Visa and at Ben-Gurion University, Israel. He is also a life member fellow in the Indian Science Congress and the Agriculture, Nutrition and Health Academy, UK. Dr. Dhruv Kumar is a Senior Associate Professor at School of Health Sciences and Technology, UPES University, Dehradun, India and his current research is focused on autophagy, cancer cell metabolism, tumour microenvironment, exosomes, mutational heterogeneity, cancer prevention, drug designing, NGS and COVID-19. After completion of B.Sc. in Chemistry from Banaras Hindu University (BHU) and M.Sc. in Bioinformatics from University of Allahabad, India, he has completed his Ph.D. in Cellular, Molecular and Industrial Biology from the University of Bologna (UNIBO), under highly prestigious fellowship, Indo-Italian Government fellowship. After his Ph.D., he obtained Postdoctoral training at the University of Kansas Medical Center, USA. During his Postdoctoral training, he worked towards understanding the molecular mechanism(s) of autophagy regulation and apoptosis in cancer stem cells (prostate, pancreatic and breast), focusing on the metabolic cross-talk between the tumour microenvironment (cancer associated fibroblast (CAF)) and head and neck squamous cell carcinoma (HNSCC) via HGF/c-MET and bFGF/FGFR signalling pathways. He has also worked on structure based drug designing for several cancers, COVID-19, mutational heterogeneity in cancer. Currently, his lab is focusing on metabolic heterogeneity in solid tumours and structure based drug designing for cancer and COVID-19. He has published more than 100 research articles, reviews and book chapters in reputed journals. Dr. Divya Singh is presently working as a scientist in Central Sericultural Research and Training Institute, Mysore, India. Her research specialization is primarily in genetics, proteomics, metabolomics, toxicology, bioinformatics, and molecular biological evaluation in various in vivo and in vitro plant models to elucidate the physiological changes and evaluate the DNA damage potency. She has published morethan 10 research articles including book chapters. In addition, she is also a life member fellow of Indian Science Congress. Dr. Rajesh Kumar Singh is currently working as a Research Associate in Banaras Hindu University. His research focus is pharmacognosy, reverse pharmacology, drug design and discovery, extraction & isolation of natural products, cell culture, and handling of different rodents. He has published several research articles in reputable journals over the course of his career. At present, he is involved in developing an Indian origin cell line and screening drugs of natural origin for the treatment of gallbladder cancer.

• 1. A historical review and future prospective of chemical carcinogenesis2. Role of xenobiotics metabolism in carcinogenesis3. Recalcitrant of toxic xenobiotics and its routes of exposure to human4. Major environmental xenobiotics risk for different cancers5. Toxicokinetic and toxicodynamic of xenobiotics in cancer development 6. Mechanism of oxidative stress in carcinogenesis induced by xenobiotics7. Genotoxic and non-genotoxic activities of cancer-inducing xenobiotics8. Modulation of epigenome by xenobiotics in cancer9. Carcinogenic effects of nanomaterials with emphasis on nanoplastics10. Endocrine disruptor activity of xenobiotics in carcinogenesis11. Environmental exposures (Bisphenol A and phatalates) as xenoestrogens enhance risk for breast cancer12. Biotransformation of toxic xenobiotics by human gut microbiota13. Mechanism of resistance to toxic xenobiotics in human14. Profiling the reactive metabolites of xenobiotics in cancer15. Toxicogenomic for prediction of carcinogenicity of xenobiotic substances